Loading data for ADMA — first visit, this takes a few seconds.
ADMA Biologics, Inc. (ADMA)
NasdaqGM: ADMA
· 即時價格 · USD
9.34
-0.14 (-1.48%)
收盤價： Sep 11, 2026, 8:00 PM
9.20
-0.33%
盤後: 7:30 PM
股價、關鍵數字和最新消息，都在這一頁。
ADMA Biologics, Inc.（ADMA）股價、分析與資料
無可用資料
| 買價 | 6.44 |
| 市值 | 2.07B |
| 營收 (ttm) | 512M |
| 淨利（ttm） | 169M |
| 0.77 | |
| 0.7 | |
| 13.38 | |
| 9.78 | |
| P/B (ttm) | 5.10 |
| P/S (ttm) | 4.04 |
| 財報日期 | Nov 4, 2026 |
| 賣價 | 11.52 |
| 成交量 | 1,835,691 |
| 20 日平均成交量 | 2,881,690 |
| 開盤價 | 9.46 |
| 前收盤價 | 9.48 |
| 當日區間 | 9.34 - 9.51 |
| 52 週範圍 | 7.21 - 20.46 |
| 分析師 | 購買 |
| 目標價 | 17.5 (87.37%) |
| 股利 | n/a |
| 除息日 | n/a |
關於 ADMA
ADMA Biologics, Inc., a biopharmaceutical company, develops, manufactures, and markets specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company operates through ADMA BioManufacturing and Plasma Collection Centers segments. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodef...
完整的公司簡介財報驚奇
ADMA Biologics 已於 Aug 5, 2026 公布季度財報：
- 營收為 $124.4M 低於預期 $0, 年增 1.98% 成長.
- 每股盈餘為 0.17 超出預期 0.01, 年增 21.43% 成長.
第 1 頁，共 2 頁